COPD combo therapy reduces death, hospitalisations

Combination therapy of long-acting beta agonists and inhaled corticosteroids (LABA-ICS) significantly lowers risk of death or COPD hospitalisation compared with LABAs alone, report Canadian researchers.

Their fiive-year study published in JAMA shows users of LABA-ICS had a 3.7% lower absolute risk of death or hospitalisation than users of LABAs alone.  

For COPD patients with asthma, the difference was 6.5%, and for patients not receiving long-acting anticholinergic medication (LAAs) the difference